ArticlePloS one2025
The Healthy Brain 9 (HB9): A new instrument to characterize subjective cognitive decline, and detect anosognosia in mild cognitive impairment.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Puppy Escape Narrative: Validation of an Openly Available Recall Task for MCI Detection.medRxiv : the preprint server for health sciences · 2026Article
Corrections and comments
- Update of
Authors and funding
11 authors.
Funding
Abstract
objectivesSubjective cognitive decline (SCD) affects 10% of older adults and may be a risk factor for future mild cognitive impairment (MCI) and dementia. Some individuals with MCI have anosognosia, the denial or lack of awareness of their cognitive deficits. We developed and tested the Healthy Brain 9 (HB9), a self-reported assessment of cognitive performance and everyday functioning, in a diverse community-based cohort of older adults in South Florida.
designCross-sectional study.
settingCommunity-based longitudinal study of brain health.
participantsA total of 344 participants (mean age of 68.5±9.3y, 70% were female, 62% with 16 or less years of education, 39% ethnoracial minorities) completed the study. The sample included 42% normal cognition, 27% SCD and 30% MCI. Within the MCI group, 62% demonstrated awareness of cognitive deficits and 38% had MCI with anosognosia. MEASUREMENTS: The psychometric properties of the HB9 were examined and the performance of the HB9 was compared to Gold Standard comprehensive clinical-cognitive-functional-behavioral evaluations and biomarkers evaluations from the Healthy Brain Initiative at the University of Miami.
resultsThe HB9 had strong psychometric properties with a Cronbach α of 0.898 (95%CI: 0.882-0.913) and low floor and ceiling effects. The HB9 performed well across different sociodemographic groups. Lower HB9 scores were associated with greater resilience, better physical performance, and less physical frailty. Higher HB9 scores were associated with more comorbid medical conditions, more mood symptoms, lower resilience, and more functional impairment. A cut-off score of 4 on the HB9 provided a 15-fold ability to detect SCD in cognitively normal individuals, and a 14-fold ability to detect anosognosia in MCI.
conclusionsThe use of the HB9 as an assessment of subjective cognitive complaints may help identify SCD for potential interventions and enrollment into clinical trials. The HB9 may also identify anosognosia which could lead to worse outcomes in MCI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.